News

Cyclacel announces development plan for its seliciclib CDK inhibitor to treat nasopharyngeal cancer BERKELEY HEIGHTS, NJ, February 5, 2007 – Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that it intends to commence in the second half of

Cyclacel Pharmaceuticals, Inc. announces quarterly dividends for 6% convertible exchangeable preferred stock BERKELEY HEIGHTS, NJ, January 30, 2007 – Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has

Cyclacel submits IND of CYC116 an Aurora kinase and VEGRF2 inhibitor to treat cancer SHORT HILLS, NJ, DECEMBER 13, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, NASDAQ: CYCCP) announced today that it has submitted an Investigational New Drug (IND) application to the Food and Drug

Cyclacel Pharmaceuticals to present at NYSSA 10th annual Biotech/Speciality Pharma Industry Conference SHORT HILLS, NJ, December 6, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the

Cyclacel reports interim Phase I data for sapacitabine in patients with advanced leukemias or myelodysplastic syndromes Short Hills, NJ, November 28, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC; Nasdaq: CYCCP) announced today interim results from a Phase I pharmacologic trial of

Cyclacel Pharmaceuticals to present at Lazard Capital Markets Life Sciences Conference Short Hills, NJ, November 17, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its

Cyclacel Pharmaceuticals reports third quarter 2006 financial results Short Hills, NJ, November 13, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) today reported financial and operating results for the third quarter 2006. The company had a net loss in the quarter of $5.4

Cyclacel reports Phase I sapacitabine study results at 18th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics meeting SHORT HILLS, NJ, November 10, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today preliminary results from a Phase I clinical trial of sapacitabine (CYC682),

Cyclacel Pharmaceuticals to announce third quarter 2006 financial results on November 13, 2006 SHORT HILLS, NJ, November 6, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) will announce third quarter 2006 financial results on Monday, November 13, 2006.

Cyclacel Pharmaceuticals to present at Rodman & Renshaw annual healthcare conference SHORT HILLS, NJ, OCTOBER 30, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that two members of its executive team will present an overview of the company and its pipeline at upcoming industry

Cyclacel Pharmaceuticals names John Womelsdorf, Ph.D., Vice President, Business Development SHORT HILLS, NJ, October 24, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that John Womelsdorf, Ph.D., has joined the company as Vice President, Business Development. Dr.

Cyclacel Pharmaceuticals to present at C.E. Unterberg, Towbin Emerging Opportunities in Healthcare Conference SHORT HILLS, NJ, OCTOBER 24, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the

Cyclacel Pharmaceuticals, Inc. announces quarterly dividend for 6% Convertible Exchangeable Preferred Stock SHORT HILLS, NJ, October 23, 2006 - Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has

Cyclacel Pharmaceuticals to present at Thomson Financial and Biocentury's: NewsMakers in the Biotech Industry Conference SHORT HILLS, NJ, SEPTEMBER 5, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an

Cyclacel Pharmaceuticals Reports Second Quarter 2006 Financial Results Short Hills, NJ, August 14, 2006 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) today reported financial and operating results for the second quarter 2006. The Company had a net loss in the quarter of $6.9

Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock SHORT HILLS, NJ, July 19, 2006 – Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has declared a

Cyclacel Begins A Phase IIb Randomized Trial Of Seliciclib For Previously Treated Non-Small Cell Lung Cancer SHORT HILLS, NJ, June 29, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the company is beginning a Phase IIb, multi-center, randomized, double-blinded trial to

Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias SHORT HILLS, NJ, JUNE 15, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the company has initiated a Phase I clinical trial of sapacitabine (CYC682), an orally available

Cyclacel Pharmaceuticals To Present At 5th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference 2006 SHORT HILLS, NJ, JUNE 12, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an

Cyclacel Pharmaceuticals To Present At Bioequity Europe 2006 SHORT HILLS, NJ, MAY 18, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, will present an overview of the Company and its pipeline at